Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 5/20 | 0.57 |
| ▸ | MMP9 | P14780 | 5/20 | 0.57 |
| ▸ | MMP8 | P22894 | 5/20 | 0.57 |
| ▸ | MMP13 | P45452 | 4/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 9/20 | 0.54 |
| ▸ | RAB9A | P51151 | 7/20 | 0.54 |
| ▸ | NPBWR1 | P48145 | 6/20 | 0.54 |
| ▸ | NPC1 | O15118 | 6/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.54 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.54 |
| ▸ | RELA | Q04206 | 3/20 | 0.54 |
| ▸ | HTT | P42858 | 3/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2578753 | 0.85 | MAPT (0.47) | MMP2MMP9MMP8MMP13MAPT | |
| SCHEMBL12286572 | 0.83 | MAPT (0.48) | MMP2MMP9MMP8MMP13MAPT | |
| SCHEMBL2250050 | 0.83 | MMP2 (0.80) | MMP2MMP9MMP8MMP13MAPT | |
| SCHEMBL9113986 | 0.82 | PRMT1 (0.56) | MMP2MMP9MMP8MMP13MAPT | |
| SCHEMBL14892425 | 0.82 | MAPT (0.45) | MMP2MMP9MMP8MMP13MAPT | |
| SCHEMBL18936884 | 0.81 | MAPT (0.43) | MMP2MMP9MMP8MMP13MAPT | |
| SCHEMBL2566093 | 0.81 | MAPT (0.43) | MMP2MMP9MMP8MMP13MAPT | |
| SCHEMBL14891836 | 0.80 | MAPT (0.41) | MMP2MMP9MMP8MMP13MAPT | |
| SCHEMBL1552598 | 0.80 | MAPT (0.54) | MAPTRAB9ANPBWR1NPC1SMN1; SMN2 | |
| SCHEMBL14891835 | 0.80 | NPBWR1 (0.42) | MMP2MMP9MMP8MMP13MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE46943-E1 | Radioprotector compounds and methods | PETER MACCALLUM CANCER INSTITUTE (AU) | 2018-07-10 | — | — | US | disclosed |
| US-8999993-B2 | Radioprotector compounds and methods | PETER MACCALLUM CANCER INSTITUTE (AU) | 2015-04-07 | — | — | US | disclosed |
| US-20130109678-A1 | RADIOPROTECTOR COMPOUNDS AND METHODS | PETER MACCALLUM CANCER INSTITUTE (AU) | 2013-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109678-A1 | RADIOPROTECTOR COMPOUNDS AND METHODS | NR1H2, NR1H3, NR1I3 | MMP2 3565/4885MMP9 3441/4885MMP8 3337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.